Enforcement alone is failing. A new governance model—integrating forensic science, community care, and real-time intelligence ...
Bright Minds Biosciences has debuted glowing phase 2 results for its lead anti-seizure asset, giving the biotech’s stock a ...
Investing.com -- Bright Minds Biosciences (NASDAQ:DRUG) stock rose 5% after the clinical-stage biotechnology company announced positive topline results from its Phase 2 BREAKTHROUGH trial for BMB-101 ...
Shares of Bright Minds Biosciences rose after the company released positive topline results from its phase two trial of a treatment for patients with drug-resistant Absence Seizures and Developmental ...
BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% ...
Bright Minds Biosciences (DRUG) stock jumps as lead drug BMB-101 succeeds in a mid-stage trial against a severe neurological ...
A long-running debate over Tamiflu’s safety in children may finally be settled. Researchers found that influenza, not the ...
TipRanks on MSN
Bright Minds Biosciences sets January 6 webcast for BMB-101 phase 2 topline results in drug-resistant absence seizures
Bright Minds Biosciences ( ($TSE:DRUG) ) has issued an update. On January 5, 2026, Bright Minds Biosciences announced plans to report topline ...
Epilepsy is not a one size fits all condition and there are a few tell tale signs that parents could miss, said Dr Jonathan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback